Fasudil hydrochloride

ApprovedSmall molecule

TTechnical University of Munich

Fasudil hydrochloride is one of 105 small molecule programs targeting Atherosclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

AtherosclerosisActive, not recruiting

Myocardial InfarctionActive, not recruiting

Ovarian CancerActive, not recruiting

Idiopathic Parkinson´s DiseaseActive, not recruiting

AtherosclerosisPhase 2

Active, not recruiting

Myocardial InfarctionApproved

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Idiopathic Parkinson´s DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

32 2

Avastin

BBio-Thera Solutions

Phase 3

83 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

22 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

21 5

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 6

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 7

Nolvadex

AstraZeneca

Phase 3

2 8

Taxotere

AAvyxa

Phase 3

11 9

Yondelis

AApotex Inc.

Phase 3

6 10

Vepesid

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Idiopathic Parkinson´s Disease

NCT05931575

Q1 2028

Phase 2Recruiting

Ovarian Cancer

NCT06890858

Clinical

Trials by Indication[1]

Vascular Function1 trial

Red Blood Cell ATP Release and Vascular Function in Humans

Completed·—·Phase 2·NCT03404843·31 enrolled

Atherosclerosis1 trial

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

Terminated·—·Phase 2·NCT00670202·2 enrolled

Ovarian Cancer1 trial

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

Recruiting·ZZhejiang Provincial People's Hospital·Phase 2·NCT06890858·20 enrolled

Myocardial Infarction1 trial

Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

Unknown status·RRenJi Hospital·Phase 4·NCT03753269·600 enrolled

Idiopathic Parkinson´s Disease1 trial

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)

Active, not recruiting·TTechnical University of Munich·Phase 2·NCT05931575·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fasudil hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fasudil hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fasudil hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Technical University of Munich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTechnical University of Munich

Fasudil hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2028

Trials by Indication[1]

Vascular Function1 trial

Atherosclerosis1 trial

Ovarian Cancer1 trial

Myocardial Infarction1 trial

Idiopathic Parkinson´s Disease1 trial

References

Drug Info

Quick Facts

Related News